Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million :: (AVTX)
Summary
We believe that HS is a multi-billion-dollar commercial opportunity and that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing, said Garry A. Neil, MD, CEO, and Chairman of the Board at Avalo. We greatly value his partnership and expertise.Patrick J. Crutcher, former CEO of AlmataBio, added, "We are pleased that Avalo recognizes the promise of AVTX-009, an important potential treatment option for patients with inflammatory diseases. The warrants are exercisable for approximately $5.80 per underlying share of common stock until the earlier of five years from the date of issuance or 30 days after the public announcement of the first patient dosed in a Phase 2 trial of AVTX-009 in HS. A replay of the webcast will also be available via under the News/Events page in the Investors section of the Avalos website approximately two hours after the calls conclusion.AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1 (IL-1) with high affinity and neutralizes its activity. There is evidence that inhibition of IL-1 could be effective in HS and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.